Lotte Hiddingh

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Corrigendum to: Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.

Corrigendum to: Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.

Journal: Neuro-oncology

Published: October 28, 2020

Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes.

Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes.

Journal: Cancer discovery

Published: September 04, 2019

Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.

Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.

Journal: Neuro-oncology

Published: November 04, 2017

A chemical screen for medulloblastoma identifies quercetin as a putative radiosensitizer.

A chemical screen for medulloblastoma identifies quercetin as a putative radiosensitizer.

Journal: Oncotarget

Published: October 04, 2015

Identification of temozolomide resistance factors in glioblastoma via integrative miRNA/mRNA regulatory network analysis.

Identification of temozolomide resistance factors in glioblastoma via integrative miRNA/mRNA regulatory network analysis.

Journal: Scientific reports

Published: April 11, 2014

EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma.

EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma.

Journal: Oncotarget

Published: February 06, 2014

Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs.

Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs.

Journal: Journal of the National Cancer Institute

Published: August 14, 2013

Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.

Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.

Journal: Hepatology (Baltimore, Md.)

Published: July 14, 2013

WEE1 kinase inhibition enhances the radiation response of diffuse intrinsic pontine gliomas.

WEE1 kinase inhibition enhances the radiation response of diffuse intrinsic pontine gliomas.

Journal: Molecular cancer therapeutics

Published: December 29, 2012

Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases.

Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: October 17, 2012

Tumor-mediated inhibition of human dendritic cell differentiation and function is consistently counteracted by combined p38 MAPK and STAT3 inhibition.

Tumor-mediated inhibition of human dendritic cell differentiation and function is consistently counteracted by combined p38 MAPK and STAT3 inhibition.

Journal: Oncoimmunology

Published: August 31, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026